When management at CannTrust announced on May 29 that a suspended

Cannabis seizures are unlikely to inspire too many positive thoughts in the minds of weed enthusiasts, but Thailand’s decision to use almost 22 tonnes of confiscated weed to help advance related medical research isn’t likely to be met with protests among too many stoners.

The Office of Narcotics Control Board (ONCB) in Thailand is divvying up a massive haul of cannabis to the benefit of 11 medical institutes and research facilities registered to use marijuana for research purposes, according to the Bankok Post.

Health Canada has been warning cannabis companies of the mislabeling of the THC contents in certain products, the Calgary Herald reported. 

According to the regulator, which is responsible for Canada’s federal health policy, most cannabis companies have been in compliance with the Cannabis Act and regulations, but there have been instances of products having as much as five times the THC content that’s advertised.

Since the legalization of recreational marijuana, Health Canada has ordered 15 recalls of products that contained mislabeled THC or CBD levels, most of which were sold as dried flower. 

When Dan Aykroyd’s Crystal Head Vodka made its Canadian debut more than a decade ago, the Liquor Control Board of Ontario banned it. It wasn’t because Akroyd was promoting the “clean” and “premium” nature of the product, or using his celebrity status to sell booze. No issues there. It was the skull-shaped bottle that had them worried. 

Health Canada has been flagging legal cannabis products containing incorrect amounts of THC content — up to five times more of the ingredient than advertised.

Since recreational legalization took effect in October 2018, the federal agency has ordered 15 recalls of products due to labelling errors in the actual levels of THC and CBD present.

In one instance, a package of pre-rolled cannabis cigarettes was determined to have five times the THC content posted.

Other instances had THC levels below that listed.

“The (federal) cannabis regulations require licence holders to investigate complaints received about the quality of cannabis and, if necessary, to take corrective measures,” Health Canada spokeswoman Tammy Jarbeau said in an email.

A few cannabis stocks made a strong comeback in May 2020. This consistent upward surge in the last month has garnered investor attention. Does this mean pot stocks are poised to move higher in the second half of 2020 and crush market returns? Or is the recent uptick a temporary recovery?

f you’ve been calling up your same dealer for over a decade, who offers potent, skunky weed for $5 a gram, why would you bother switching over to Canada’s new regulated cannabis market?

That’s a question industry players should have focused on when the Cannabis Act passed on Oct. 17, 2018, according to Michael Armstrong, an associate professor at Brock University.

In those early days, the professor says corporate cannabis was too busy bragging about square meters of growing space rather than zeroing in on what consumers actually want: cheap, quality weed.

Looking back on covering legalization and its evolving cannabis culture for the last three years, it’s tough to choose a single anecdote that best illustrates why I do so much cringing behind the scenes.

Before COVID-19 made it impossible, Dan Larocque and a friend would meet up two or three times a month for “Hash Day” — a precious few hours devoted to making their own hash.

The process is a bit of a to-do. The pair combines homegrown, harvested cannabis with ice water in a portable washing machine. The mixture is eventually dumped out into a bucket with stacks of screening bags inside. Each bag is then drained, as resin heads are collected at the bottom.

The Canadian Paediatric Society has issued guidelines to help doctors screen teenage patients for problematic use of recreational cannabis.

The group says it's critical to raise the issue regularly, pointing to a recent survey that found 44 per cent of youth aged 16 to 19 reported using cannabis within the previous year.

It encourages doctors to suggest meeting patients alone for at least part of their appointments starting at age 12, in case they are reluctant to disclose risky behaviour in front of their parents.

Health-care professionals should also ask their young patient's permission to discuss cannabis, guarantee confidentiality, answer questions honestly and assess how cannabis may be affecting family life, school, work and relationships.